Efficacy and safety of etanercept in patients with psoriasis and hepatitis C by Ventura, F et al.
CORRESPONDENCE
Efficacy and safety of etanercept
in patients with psoriasis and hepatitis C
Patients with psoriasis and concomitant hepatitis C virus
(HCV) infection present a therapeutic challenge. The
treatment of choice for HCV infection, interferon-α
(IFN-α), might be a precipitating or aggravating factor
for psoriasis. On the other hand, the standard systemic
therapies for psoriasis, cyclosporine, methotrexate and
acitretin, with their hepatotoxic or immunosuppressive
potentials should be avoided in these patients [1].
A 35-year-old man with psoriasis since 1990 and HCV
infection, genotype 3, diagnosed in 1997, had never
required antiviral therapy. He had previously been treated
with topical agents and ultraviolet-B (UVB) phototherapy
with inadequate control of his psoriasis. He received
cyclosporine, 3 mg/kg/day, after consultation with a
gastroenterologist, with a good response, but decided to
stop the treatment after leaving the Hospital in 2003.
One year ago, the patient returned to our Department
because the psoriasis had progressively deteriorated. He
confessed self-medication with cyclosporine and clobeta-
sol propionate ointment during the past 5 years, when the
psoriasis worsened. On physical examination he presented
with widespread plaque psoriasis on erythematous skin
(figure 1A). The Psoriasis Area and Severity Index
(PASI) was 30. Etanercept 25 mg sc twice a week was
started. We consulted the patient’s gastroenterologist
before initiating therapy. An excellent response was
observed (figure 1B), with a PASI of 6.6 and 3 after
12 and 24 weeks respectively. No relevant changes in
liver function tests were noted but the treatment had to
be stopped after 6 months due to an increase of the viral
load (table 1).
A 47-year-old woman with HCV infection, genotype 1b,
diagnosed in 1993, was initially treated with IFN-α, which
was discontinued after several months because of the
appearance of typical psoriatic lesions. The psoriasis was
treated with topical agents and UVB phototherapy, with-
out a complete response.
Physical examination showed extensive erythematous
hyperkeratotic plaques on the trunk, arms and legs, with
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Figure 1. A) Patient 1: Extensive psoriasic lesions. B)
Marked improvement of the lesions after 24 weeks of treat-
ment.
Table 1. Liver parameters and viral load for 2 patients with HCV infection treated with etanercept for psoriasis
Patient 1
ALT (U/L) AST (U/L) γ-GT (U/L) HCV RNA (IU/mL)
Baseline 36 47 54 1.63×104
1 month 40 50 53 1.50×104
3 months 45 68 51 1.52×104
6 months 44 39 45 1.94×106
Patient 2
ALT (U/L) AST (U/L) γ-GT (U/L) HCV RNA (IU/mL)
Baseline 40 46 63 1.0×107
1 month 45 48 72 7.67×106
3 months 35 47 64 5.11×106
6 months 36 65 78 5.15×106
9 months 38 63 83 4,86×106
12 months 31 51 74 3.92×106
15 months 35 37 67 3,11×106
18 months 36 39 67 3.12×106
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a PASI of 17.5. She had also psoriatic arthritis mainly of
the interphalangeal regions of fingers and toes. Treatment
with etanercept, 50 mg/week administered as a single sub-
cutaneous injection, was prescribed after consultation with
a gastroenterologist. After 1 month her psoriasis plaques
thinned, became less red and the scale disappeared. After
12 and 24 weeks of treatment her PASI was 4 and 0
respectively. The joint pains disappeared. On serologic
evaluations there was no worsening of the liver function
tests (table 1). The patient continued the treatment with a
sustained decrease in the viral load after 18 months
(table 1).
There are some small-scale studies involving the use of
etanercept on patients with HCV infection [2, 3], as well
as case reports of a limited number of patients being trea-
ted for rheumatoid arthritis, psoriasis and ankylosing
spondylitis [1, 4, 5]. The safety profile of TNF-α blockers
in patients with HCV infection remains a concern because
of risks associated with immune suppression. However
they are not directly hepatotoxic, so seem to be a good
alternative in individuals with liver disease.
Potentially relevant is the fact that high levels of TNF-α
have been documented in patients with HCV infection and
associated with a worse prognosis regarding hepatic fibro-
sis. Zein showed that etanercept may also be safe and
effective as an adjuvant therapy to IFN-α and ribavirin
for HCV infection [6].
We report two more patients with psoriasis and HCV
infection treated with etanercept, without worsening of
their liver function tests. However, one patient showed
an increase in viral load after 6 months of treatment, so
it was stopped. The other patient continued the treatment
with a sustained decrease in viral load after 18 months. ■
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Buruli ulcer caused by “Mycobacterium
ulcerans subsp. shinshuense”
Buruli ulcer (BU) is a necrotizing disease of the skin
caused by Mycobacterium ulcerans (M. ulcerans), occur-
ring mainly in tropical areas [1]. In Japan, BU is
extremely rare and there have only been 8 reports so far
[2-4].
A 46-year-old-man presented with a 9-day history of
swelling on the right dorsal foot. Physical examination
revealed a painless swelling with flare and a vesicle on
his right dorsal foot (figure 1A). We suspected an insect
bite and treated the lesion with oral administration of pre-
donisolone (30 mg/day). The symptoms improved imme-
diately but worsened with a reduction in the dose of pre-
donisolone. Results of routine laboratory investigations
were within normal limits. A skin biopsy at day
20 revealed papillary dermal edema and necrobiosis of
the dermis (figure 1B). Based on these findings, we sus-
pected a persistent insect bite and continued oral predoni-
solone. However, the response was poor and we took
another biopsy at day 51.
Histopathological examination revealed dense neutro-
philic infiltration without vasculitis, from the upper der-
mis to subcutaneous tissue. Cultures of microorganisms
were all negative. Based on these results, we suspected
neutrophilic dermatosis and treated with oral prednisolone
(5-30 mg/day). The lesions gradually formed a painless
ulceration with necrotic masses (figure 1C). A smear
from the ulcer at day 185 revealed acid-fast reddish rods
by Ziehl-Neelsen staining, but we detected no organism
by culture. At this time, we retrospectively performed
Ziehl-Neelsen staining on the histological section of the
first biopsy specimen and detected many acid-fast bacilli
(figure 1D). Polymerase chain reaction (PCR) of necrotic
tissue revealed positive reactions to genes, suggesting M.
ulcerans subsp. Shinshuense infection. A chest X-ray and
computed tomography scan of the whole body revealed
no abnormalities. Based on these results, a diagnosis of
Buruli ulcer caused by M. ulcerans subsp. Shinshuense
was made.
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Figure 1. A) Swelling with flare and vesicle on the right dor-
sal foot. B) Ulceration with necrotic masses. C) Papillary
edema and necrosis of dermis (H and E staining; original
magnification ×40). D) Ziehl-Neelsen staining revealed many
acid-fast bacilli in the dermis (original magnification ×100).
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